We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A bis-boron boramino acid PET tracer for brain tumor diagnosis.
- Authors
Li, Zhu; Chen, Junyi; Kong, Ziren; Shi, Yixin; Xu, Mengxin; Mu, Bo-Shuai; Li, Nan; Ma, Wenbin; Yang, Zhi; Wang, Yu; Liu, Zhibo
- Abstract
Purpose: Boramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the 18F-labeled positron emission tomography (PET) and boron neutron capture therapy (BNCT) with identical chemical structure. Methods: This study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging. Results: Competition inhibition assays in cancer cells suggested the cell accumulation of [18F]BBPA is through large neutral amino acid transporter type-1 (LAT-1). Of note, [18F]BBPA is a pan-cancer probe that shows notable tumor uptake in B16-F10 tumor-bearing mice. In the patients with gliomas and metastatic brain tumors, [18F]BBPA-PET shows good tumor uptake and notable tumor-to-normal brain ratio (T/N ratio, 18.7 ± 5.5, n = 11), higher than common amino acid PET tracers. The [18F]BBPA-PET quantitative parameters exhibited no difference in diverse contrast-enhanced status (P = 0.115–0.687) suggesting the [18F]BBPA uptake was independent from MRI contrast-enhancement. Conclusion: This study outlines a clinical trial with [18F]BBPA to achieve higher tumor-specific accumulation for PET, provides a potential technique for brain tumor diagnosis, and might facilitate the BNCT of brain tumors.
- Subjects
CONTRAST-enhanced magnetic resonance imaging; CANCER diagnosis; BORON-neutron capture therapy; POLYETHYLENE terephthalate; POSITRON emission tomography; BRAIN tumors; BINDING site assay
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2024, Vol 51, Issue 6, p1703
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-024-06600-5